Tue, Jul 22, 2014, 4:12 PM EDT - U.S. Markets closed

Recent

% | $
Click the to save as a favorite.

Neostem, Inc. Message Board

  • bob_flemings bob_flemings Oct 30, 2012 5:15 PM Flag

    NBS' strong position as a Contract Manufacturing Organization (CMO)

    The company has an impressive cell therapy manufacturing division in its Progenitor Cell Therapy (PCT) subsidiary. With over 65,000 square feet of developing and manufacturing space between its Allendale, NJ and its Mountain View, CA facilities, the company has participated in more than 50 regulatory filings in the U.S. and Europe. The company boasts experience in more than 20 cell/tissue types with more than 5,000 patients receiving therapies produced at its facilities with more than 30,000 cell therapy procedures performed.

    Already achieving recognition as the Phase III clinicals provider of Dendreon's (DNDN) Provenge, the author believes much of Dendreon's cost issues could have been averted if the company had continued its contract with PCT beyond the development stage and on into the commercialization phase. The uncertainty facing stem cell companies and immunotherapy companies not only in the development stages of development but even into the commercialization stages of growth can be formidable. NeoStem's expertise and state-of-the-art facilities may prove to be huge sources of revenue in the coming months and years as the immunotherapy and stem cell approaches gain more validity and approvals. Investors desiring to have exposure to the immunotherapy approach to fighting cancer and stem cell therapy for fighting a host of indications may find the best of both worlds here in NeoStem's PCT division. This year alone the company has already announced partnerships with SOTIO, LLC for the U.S. portion of a pivotal Phase III trial for SOTIO's autologous dendritic cell vaccine, a partnership with Baxter International to produce a Phase III CD34+ stem cell therapy to target chronic myocardial ischemia and an increased partnership with ImmunoCellular Therapeutics (IMUC) to produce the company's ICT-107 immunotherapy product for its Phase II trial to treat the brain cancer, glioblastoma.

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
NBS
6.01+0.08(+1.35%)4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.